Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Clinical evidence

RAPIDe-2

55 evidence topics · 7 sources

Objective
Location and study date
Registry dates, status, and number of locations
FieldReported value
Recruitment status“Enrolling by invitation”
Study start (actual)“2022-12-28”
Primary completion (estimated)“2027-06”
Study completion (estimated)“2027-06”
First posted“2022-05-31”
Last update posted“2026-07-21”
Locations“This study has 60 locations”
Study design
Registry design details
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Part A participants, combined dose group (N=19)
CharacteristicDeucrictibant IR capsule, combined dose group
Age in years, mean (SD)“44.4 (17.6)”
Sex: male / female, n (%)“7 (36.8) / 12 (63.2)”
Race: White / other, n“18 / 1”
BMI, mean (SD)“26.8 (4.0)”
Years since HAE diagnosis, mean (SD)“23.3 (15.2)”
HAE-1, n (%)“17 (89.5)”
HAE-2, n (%)“2 (10.5)”
Participants with and without upper airway attacks
CharacteristicWith ≥1 upper airway attack (n=7)Without upper airway attacks (n=12)
Age in years, mean (SD)“46.0 (19.5)”“43.4 (17.2)”
Sex: male / female, n (%)“4 (57) / 3 (43)”“3 (25) / 9 (75)”
Race: White / other, n“7 / 0”“11 / 1”
BMI, mean (SD)“27.1 (3.8)”“26.7 (4.2)”
Years since HAE diagnosis, mean (SD)“20.8 (18.9)”“24.7 (13.3)”
HAE-1, n (%)“6 (85.7)”“11 (91.7)”
HAE-2, n (%)“1 (14.3)”“1 (8.3)”
Efficacy results
Median time to key efficacy endpoints, Part A (465 attacks)
EndpointMedian time95% CI
Onset of symptom relief (PGI-C)“1.1 hours”“(1.0, 1.1)”
Substantial symptom relief (PGI-C)“2.5 hours”“(2.1, 2.9)”
Reduction in attack severity (PGI-S)“2.8 hours”“(2.3, 2.9)”
Complete attack resolution (PGI-S)“10.6 hours”“(8.5, 11.5)”
Proportion of attacks achieving key endpoints, evaluable attacks (457 PGI-C, 449 PGI-S)
EndpointProportion of attacksAttacks
Onset of symptom relief by 12 hours“97.8%”“447/457”
Substantial symptom relief by 12 hours“95.2%”“435/457”
Reduction in attack severity by 12 hours“96.7%”“434/449”
Complete symptom resolution at 24 hours“86.9%”“390/449”
Attacks treated with a single dose and rescue medication use, evaluable attacks (457)
AttacksOne doseTwo doses
Overall“86.2%”“394/457”“13.8%”“63/457”
Complete attack resolution within 24 hours“89.2%”“348/390”“10.8%”“42/390”
Upper airway attacks compared with non-upper airway attacks, post hoc analysis
EndpointUpper airway attacks (n=7 participants)Non-upper airway attacks in participants with upper airway attacks (n=7)All non-upper airway attacks (n=19)
Total number of attacks treated“14”“177”“451”
Time to onset of symptom relief, median hours (95% CI)“1.4 (0.8–3.0)”“1.0 (1.0–1.2)”“1.1 (1.0–1.1)”
Time to substantial symptom relief, median hours (95% CI)“3.6 (2.0–6.1)”“2.7 (2.1–3.0)”“2.4 (2.1–2.8)”
Time to reduction in attack severity, median hours (95% CI)“1.8 (0.9–3.0)”“2.1 (2.0–2.8)”“2.8 (2.4–2.9)”
Time to complete attack resolution, median hours (95% CI)“8.9 (3.9–36.3)”“8.0 (7.3–10.7)”“10.6 (8.5–11.5)”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events within 3 days of study drug, Part A (N=19; 465 attacks)
Adverse eventsDeucrictibant IR capsule, combined dose group
Attacks with any TEAE, n (%)“12 (2.6)”
Treatment-related TEAEs, n“0”
Serious TEAEs, n“1”
Treatment-related serious TEAEs, n“0”
TEAEs leading to study drug discontinuation, study withdrawal, or death, n“0”
Study limitations
Summary
  • RAPIDe-2 is a single-group study with no control arm, and its registry record lists no masking. In Part A, participants were blinded to dose while every attack was treated with active drug. The registry states the primary safety analysis is “Descriptive in nature, no formal statistical hypothesis testing will be performed”.
  • Part A included 19 adults, all from RAPIDe-1, who contributed 465 attacks; long-term prophylaxis was not allowed and 18 of the 19 were White. Results were reported for the combined 10 mg, 20 mg, and 30 mg dose group.
  • Denominators vary by endpoint: 457 attacks had post-treatment PGI-C data and 449 had pre-treatment and post-treatment PGI-S data, and the single-dose proportion is reported as 394/457 and as 395/465. “Within-participant correlation was not accounted for in all Kaplan–Meier estimates”.
  • Upper airway results rest on 14 attacks in seven participants.
  • Rescue medication use within 14.5 hours led to censoring at 14.5 hours, and baseline values for constant parameters were taken from RAPIDe-1.
  • Planned enrollment is 150 in ClinicalTrials.gov and 72 in the EU register. “The RAPIDe-2 study is still ongoing”, with primary completion estimated for 2027-06. Part A results come from documents on the company's investor website and the company's annual report, and Part B results are limited to cardiovascular events in 110 participants.